Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genakumab alone and with Tislelizumab in advanced solid tumors
NCT05441046Phase 1Unknown
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of genakumab in Advanced Malignant Solid Neoplasm (AMSN), colorectal cancer (CRC) and pancreatic cancer (PC) (5 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 6 months and 8 more. Status: unknown.
02
Drugs
genakumab
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05441046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441046.